|
Mutation Information
|
Mutation Site
|
M184V |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Country
|
Canada |
Literature Information
|
PubMed PMID
|
33204746
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2020 |
|
Journal
|
Open forum infectious diseases |
|
Title
|
Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World Data. |
|
Author
|
Sangaré MN,Baril JG,de Pokomandy A,Ferreira Guerra S,Carabali M,Laprise C,Thomas R,Klein M,Tremblay C,Roger M,Pexos C,Greenwald ZR,Machouf N,Durand M,Hardy I,Dakouo M,Trevisan A,Laporte L,Schnitzer ME,Trottier H |
|
Evidence
|
Among the 25 PWH with M184V whose regimen was switched to dolutegravir, 60% (15 of 25) included the backbone abacavir/lamivudine and 40% (10 of 25) included tenofovir disoproxil fumarate/emtricitabine.
|
|
|
HIV Mutation Detail Information